Abstract
The intracellular pathways leading to mitochondrial activation and subsequent cell death in the ceramide-mediated stress response have been intensively studied in recent years. Experimental evidence has been provided that ceramide-induced apoptosis is inhibited by overexpression of antiapoptotic proteins of the Bcl-2 family. However, the direct effect of proapoptotic gene products, e.g. Bax, on ceramide-induced death signalling has not yet been studied in detail. In the present work, we show by measurement of mitochondrial permeability transition, cytochrome c release, activation of caspase-3 and DNA fragmentation that ceramide-induced apoptosis is marginal in Bax-negative DU 145 cells. Reconstitution of Bax by generation of DU 145 cells stably expressing this proapoptotic factor, clearly enhanced ceramide-induced apoptosis at all levels of the mitochondrial signalling cascade. Using the broad-range caspase inhibitor zVAD-fmk and zDEVD-fmk, an inhibitor of caspase-3-like activities, we demonstrate that the ceramide-induced mitochondrial activation in Bax-transfected DU 145 cells is caspase-independent. On the other hand, apoptotic events located downstream of the mitochondria, e.g. DNA fragmentation, were shown to be caspase-dependent. This influence of Bax on ceramide-induced apoptosis was confirmed in another cellular system: whereas Bax-positive HCT116 wild type cells were very sensitive towards induction of cell death by C2-ceramide, sensitivity of Bax knock-out HCT116 cells was significantly reduced. Thus, we conclude that Bax is a key activator of ceramide-mediated death pathways.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adams JM, Cory S . 1998 Science 281: 1322–1326
Bargou RC, Wagener C, Bommert K, Mapara MY, Daniel PT, Arnold W, Dietel M, Guski H, Feller A, Royer HD, Dörken B . 1996 J. Clin. Invest. 97: 2651–2659
Basu S, Bayoumy S, Zhang Y, Lozano J, Kolesnick R . 1998 J. Biol. Chem. 273: 30419–30426
Belaud-Rotureau MA, Leducq N, Macouillard Poulletier de Gannes F, Diolez P, Lacoste L, Lacombe F, Bernard P, Belloc F . 2000 Apoptosis 5: 551–560
Bielawska A, Linardic CM, Hannun YA . 1992 J. Biol. Chem. 267: 18493–18497
Blagosklonny MV . 2000 Leukemia 14: 1502–1508
Cifone MG, Roncaioli P, De Maria R, Camarda G, Santoni A, Ruberti G, Testi R . 1995 EMBO J. 14: 5859–5868
Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK . 1995 J. Virol. 69: 7430–7436
Daniel PT . 2000 Leukemia 14: 2035–2044
Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S, Maundrell K, Antonsson B, Martinou JC . 1999 J. Cell. Biol. 144: 891–901
Dragovich T, Rudin CM, Thompson CB . 1998 Oncogene 17: 3207–3213
Engedal N, Saatcioglu F . 2001 Prostate 46: 289–297
Eskes R, Desagher S, Antonsson B, Martinou J C . 2000 Mol. Cell. Biol. 20: 929–935
Essmann F, Wieder T, Otto A, Muller EC, Dorken B, Daniel PT . 2000 Biochem J. 346: 777–783
Geilen CC, Bektas M, Wieder T, Orfanos CE . 1996 FEBS Lett. 378: 88–92
Geilen CC, Bektas M, Wieder T, Kodelja V, Goerdt S, Orfanos CE . 1997a J. Biol. Chem. 272: 8997–9001
Geilen CC, Wieder T, Orfanos CE . 1997b Arch. Dermatol. Res. 289: 559–566
Geley S, Hartmann BL, Kofler R . 1997 FEBS Lett. 400: 15–18
Ghafourifar P, Klein SD, Schucht O, Schenk U, Pruschy M, Rocha S, Richter C . 1999 J. Biol. Chem. 274: 6080–6084
Hannun YA . 1997 Blood 89: 1845–1853
Hannun YA, Luberto C . 2000 Trends Cell. Biol. 10: 73–80
Jaffrezou JP, Bruno AP, Moisand A, Levade T, Laurent G . 2001 FASEB J. 15: 123–133
Kim HJ, Mun JY, Chun YJ, Choi KH, Kim MY . 2001 FEBS Lett. 505: 264–268
Kolesnick RN, Krönke M . 1998 Annu. Rev. Physiol. 60: 643–665
Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC . 1995 Cancer Res. 55: 4471–4478
Krammer PH . 2000 Nature 407: 789–795
Kroemer G, Reed JC . 2000 Nat. Med. 6: 513–519
Laemmli UK . 1970 Nature 227: 680–685
Lee Y, McKinnon PJ . 2000 Apoptosis 5: 523–529
Li H, Zhu H, Xu CJ, Yuan J . 1998 Cell 94: 491–501
Liu B, Obeid LM, Hannun YA . 1997 Semin. Cell Dev. Biol. 8: 311–322
Liu YY, Han TY, Giuliano AE, Cabot MC . 1999 J. Biol. Chem. 274: 1140–1146
Lotem J, Sachs L . 1993 Cell Growth Differ. 4: 41–47
Lucci A, Giuliano AE, Han TY, Dinur T, Liu YY, Senchenkov A, Cabot MC . 1999a Int. J. Oncol. 15: 535–540
Lucci A, Han TY, Liu YY, Giuliano AE, Cabot MC . 1999b Int. J. Oncol. 15: 541–546
Malisan F, Testi R . 1999 FEBS Lett. 452: 100–103
Marcelli M, Marani M, Li X, Sturgis L, Haidacher SJ, Trial JA, Mannucci R, Nicoletti I, Denner L . 2000 Prostate 42: 260–273
Martinou JC, Green DR . 2001 Nat. Rev. Mol. Cell. Biol. 2: 63–67
Meier P, Finch A, Evan G . 2000 Nature 407: 796–801
Miyashita T, Reed JC . 1993 Blood 81: 151–157
Obeid LM, Linardic CM, Karolak LA, Hannun YA . 1993 Science 259: 1769–1771
Pastorino JG, Tafani M, Rothman RJ, Marcinkeviciute A, Hoek JB, Farber JL, Marcineviciute A . 1999 J. Biol. Chem. 274: 31734–31739
Peltenburg LT . 2000 Q. J. Nucl. Med. 44: 355–364
Perry DK, Carton J, Shah AK, Meredith F, Uhlinger DJ, Hannun YA . 2000 J. Biol. Chem. 275: 9078–9084
Prokop A, Wieder T, Sturm I, Essmann F, Seeger K, Wuchter C, Ludwig W-D, Henze G, Dörken B, Daniel PT . 2000 Leukemia 14: 1606–1613
Radetzki S, Köhne CH, von Haefen C, Gillissen B, Sturm I, Dörken B, Daniel PT . 2002 Oncogene 21: 227–238
Raisova M, Bektas M, Wieder T, Daniel P, Eberle J, Orfanos CE, Geilen CC . 2000 FEBS Lett. 473: 27–32
Raisova M, Hossini AM, Eberle J, Riebeling C, Wieder T, Sturm I, Daniel PT, Orfanos CE, Geilen CC . 2001 J. Invest. Dermatol. 117: 333–340
Sawada M, Nakashima S, Banno Y, Yamakawa H, Hayashi K, Takenaka K, Nishimura Y, Sakai N, Nozawa Y . 2000a Cell Death Differ. 7: 761–772
Sawada M, Nakashima S, Banno Y, Yamakawa H, Takenaka K, Shinoda J, Nishimura Y, Sakai N, Nozawa Y . 2000b Oncogene 19: 3508–3520
Slee EA, Keogh SA, Martin SJ . 2000 Cell Death Differ. 7: 556–565
Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC . 1985 Anal. Biochem. 150: 76–85
Smyth MJ, Perry DK, Zhang J, Poirier GG, Hannun YA, Obeid LM . 1996 Biochem. J. 316: 25–28
Sturm I, Köhne C-H, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dörken B, Daniel PT . 1999 J. Clin. Oncol. 17: 1364–1374
Sturm I, Petrowsky H, Volz R, Lorenz M, Radetzki S, Hillebrand T, Wolff G, Hauptmann S, Dörken B, Daniel PT . 2001 J. Clin. Oncol. 19: 2272–2281
Weinmann P, Bommert K, Mapara MY, Dorken B, Bargou RC . 1997 Eur. J. Immunol. 27: 2466–2468
Wieder T, Geilen CC, Kolter T, Sadeghlar F, Sandhoff K, Brossmer R, Ihrig P, Perry D, Orfanos CE, Hannun YA . 1997 FEBS Lett. 411: 260–264
Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, Beyaert R, Dörken B, Daniel PT . 2001 Blood 97: 1378–1387
Zhang J, Alter N, Reed JC, Borner C, Obeid LM, Hannun YA . 1996 Proc. Natl. Acad. Sci. USA 93: 5325–5328
Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B . 2000 Science 290: 989–992
Zhang Y, Mattjus P, Schmid PC, Dong Z, Zhong S, Ma WY, Brown RE, Bode AM, Schmid HH . 2001 J. Biol. Chem. 276: 11775–11782
Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB . 2001 Genes Dev. 15: 1481–1486
Acknowledgements
This work was supported by grants from the Deutsche Forschungsgemeinschaft (SFB 506) to PT Daniel, the European Community TMR Programme to PT Daniel, the Deutsche José Carreras Leukämie-Stiftung e. V. (DJCLS-R01/02) to PT Daniel and T Wieder, the Verein zur Förderung der Tagesklinik e. V. and the Berliner Krebsgesellschaft e. V. to T Wieder. The authors want to thank Bert Vogelstein (Johns Hopkins University School of Medicine, Baltimore, MD, USA) for kindly providing HCT116 wild type and Bax −/− cells. The excellent technical assistance of Verena Lehmann is gratefully acknowledged.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
von Haefen, C., Wieder, T., Gillissen, B. et al. Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells. Oncogene 21, 4009–4019 (2002). https://doi.org/10.1038/sj.onc.1205497
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205497
Keywords
This article is cited by
-
Sperm capacitation and transcripts levels are altered by in vitro THC exposure
BMC Molecular and Cell Biology (2023)
-
Ceramide from sphingomyelin hydrolysis induces neuronal differentiation, whereas de novo ceramide synthesis and sphingomyelin hydrolysis initiate apoptosis after NGF withdrawal in PC12 Cells
Cell Communication and Signaling (2022)
-
The aetiology and molecular landscape of insulin resistance
Nature Reviews Molecular Cell Biology (2021)
-
Hsp60 and IL-8 axis promotes apoptosis resistance in cancer
British Journal of Cancer (2019)
-
The investigation of ceranib-2 on apoptosis and drug interaction with carboplatin in human non small cell lung cancer cells in vitro
Cytotechnology (2018)